

Celine C Berthier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8875133/publications.pdf>

Version: 2024-02-01

34
papers

3,642
citations

304743

22
h-index

361022

35
g-index

37
all docs

37
docs citations

37
times ranked

5502
citing authors

#	ARTICLE	IF	CITATIONS
1	Urine Single-Cell RNA Sequencing in Focal Segmental Glomerulosclerosis Reveals Inflammatory Signatures. <i>Kidney International Reports</i> , 2022, 7, 289-304.	0.8	21
2	Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1329-1339.	2.9	40
3	Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 829-839.	5.6	38
4	Glomerular endothelial cell-podocyte stresses and crosstalk in structurally normal kidney transplants. <i>Kidney International</i> , 2022, 101, 779-792.	5.2	11
5	Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation. <i>Science Translational Medicine</i> , 2022, 14, eabn2263.	12.4	52
6	Comparison of Lesional Juvenile Myositis and Lupus Skin Reveals Overlapping Yet Unique Disease Pathophysiology. <i>Arthritis and Rheumatology</i> , 2021, 73, 1062-1072.	5.6	13
7	Gene expression profiles of diabetic kidney disease and neuropathy in eNOS knockout mice: Predictors of pathology and RAS blockade effects. <i>FASEB Journal</i> , 2021, 35, e21467.	0.5	10
8	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. <i>Lupus Science and Medicine</i> , 2021, 8, e000522.	2.7	5
9	Reversible dysregulation of renal circadian rhythm in lupus nephritis. <i>Molecular Medicine</i> , 2021, 27, 99.	4.4	4
10	Exome Chip Analyses and Genetic Risk for IgA Nephropathy among Han Chinese. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 213-224.	4.5	14
11	B Cell Signatures Distinguish Cutaneous Lupus Erythematosus Subtypes and the Presence of Systemic Disease Activity. <i>Frontiers in Immunology</i> , 2021, 12, 775353.	4.8	24
12	Staphylococcus aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by IFN-Mediated Barrier Disruption. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1066-1074.e4.	0.7	34
13	SARS-CoV-2 receptor networks in diabetic and COVID-19-associated kidney disease. <i>Kidney International</i> , 2020, 98, 1502-1518.	5.2	64
14	Single cell transcriptomics identifies focal segmental glomerulosclerosis remission endothelial biomarker. <i>JCI Insight</i> , 2020, 5, .	5.0	108
15	Integrated urine proteomics and renal single-cell genomics identify an IFN- γ response gradient in lupus nephritis. <i>JCI Insight</i> , 2020, 5, .	5.0	57
16	IL18-containing 5-gene signature distinguishes histologically identical dermatomyositis and lupus erythematosus skin lesions. <i>JCI Insight</i> , 2020, 5, .	5.0	27
17	Molecular Profiling of Cutaneous Lupus Lesions Identifies Subgroups Distinct from Clinical Phenotypes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1244.	2.4	45
18	IFN- γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	85

#	ARTICLE	IF	CITATIONS
19	The immune cell landscape in kidneys of patients with lupus nephritis. <i>Nature Immunology</i> , 2019, 20, 902-914.	14.5	501
20	Hypersensitive IFN Responses in Lupus Keratinocytes Reveal Key Mechanistic Determinants in Cutaneous Lupus. <i>Journal of Immunology</i> , 2019, 202, 2121-2130.	0.8	44
21	Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1653-1664.	0.9	162
22	Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon-Induced Up-Regulation of Interferon Regulatory Factor 1. <i>Arthritis and Rheumatology</i> , 2017, 69, 1840-1849.	5.6	75
23	A gene network regulated by the transcription factor VGLL3 as a promoter of sex-biased autoimmune diseases. <i>Nature Immunology</i> , 2017, 18, 152-160.	14.5	98
24	ABIN1 Determines Severity of Glomerulonephritis via Activation of Intrinsic Glomerular Inflammation. <i>American Journal of Pathology</i> , 2017, 187, 2799-2810.	3.8	12
25	Transcriptomic and Proteomic Profiling Provides Insight into Mesangial Cell Function in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2961-2972.	6.1	65
26	A systems approach to renal inflammation in SLE. <i>Clinical Immunology</i> , 2017, 185, 109-118.	3.2	13
27	Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. <i>Science Translational Medicine</i> , 2015, 7, 316ra193.	12.4	304
28	The Molecular Phenotype of Endocapillary Proliferation: Novel Therapeutic Targets for IgA Nephropathy. <i>PLoS ONE</i> , 2014, 9, e103413.	2.5	30
29	Identification of Stage-Specific Genes Associated With Lupus Nephritis and Response to Remission Induction in (NZB × NZW)F1 and NZM2410 Mice. <i>Arthritis and Rheumatology</i> , 2014, 66, 2246-2258.	5.6	50
30	Lupus Nephritis Susceptibility Loci in Women with Systemic Lupus Erythematosus. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2859-2870.	6.1	117
31	Cross-Species Transcriptional Network Analysis Defines Shared Inflammatory Responses in Murine and Human Lupus Nephritis. <i>Journal of Immunology</i> , 2012, 189, 988-1001.	0.8	196
32	From the Large Scale Expression Analysis of Lupus Nephritis to Targeted Molecular Medicine. <i>Journal of Data Mining in Genomics & Proteomics</i> , 2012, 03, .	0.5	10
33	Netting Neutrophils Induce Endothelial Damage, Infiltrate Tissues, and Expose Immunostimulatory Molecules in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2011, 187, 538-552.	0.8	1,039
34	Enhanced Expression of Janus Kinase-Signal Transducer and Activator of Transcription Pathway Members in Human Diabetic Nephropathy. <i>Diabetes</i> , 2009, 58, 469-477.	0.6	262